Use of venetoclax in transplant conditioning regimen shows promise in myeloid cancers

(Dana-Farber Cancer Institute) For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients' bodies.